Illumina, Inc. (ILMN)
Nasdaq · Healthcare · Diagnostics & Research
$293.69+7.56%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $44.4B
- P/E (trailing)
- 54.8
- Forward P/E
- 48.1
- 52-week range
- $88.00 – $296.25
- 52-week change
- +182.42%
- EPS (trailing)
- $5.36
- Analyst rating
- 2.4 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $4.3B (−0.66%)
- Net income
- $850M
- Operating margin
- 18.6%
- Diluted EPS
- $5.45
- Free cash flow
- $931M
From the company’s annual report on SEC EDGAR.
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc.
Headquarters: San Diego, United States · 8,600 employees · illumina.com